Smoking and osseointegration: the risk downplayed to close the sale

Implants work in plenty of smokers. That is true, it is important, and it is the fact this entire article has to start with, because the dishonest version of the smoking story comes in two flavours and both are wrong. One pretends smokers cannot have implants at all. The other pretends smoking barely matters. The first is scaremongering. The second is a sales technique. Implants succeed in many smokers, and smoking is not a disqualifier [1].

Here is the pivot. The reason the second flavour is so effective is that it is built on a truth. Because many smokers do fine, a clinic can say “we place implants in smokers all the time” and never technically lie, while quietly leaving out the part where the failure rate is roughly double [1]. That omission is not random. It tracks exactly where the commercial pressure is highest, and on a one-trip overseas model the pressure to close the sale is intense while the cost of a failure that surfaces months later, on another continent, falls almost entirely on the patient. This is the What the Intake Form Skips entry where the problem is not a missing test or a missing question. The smoking is known. It is the number that gets rounded down to close the sale.

The number, stated honestly

Across independent systematic reviews and meta-analyses, dental implant failure in smokers runs at roughly twice the rate seen in non-smokers [1]. Pooled odds ratios in this literature commonly land in the region of 2.0 to 2.6, depending on which studies are included, how failure is defined, and which sites are examined. The precise figure moves around. The direction and the rough magnitude do not: independent analyses keep arriving at “about double.”

Let me be careful about what that does and does not mean, because the honesty of the framing is the whole point. Roughly doubled relative risk is not the same as “most implants fail in smokers.” Implant success rates in non-smokers are high, so doubling a small failure rate still leaves a majority of implants succeeding. A smoker is not being told their implant will fail. They are being told their chance of failure is meaningfully higher than the figure they would have been quoted as a non-smoker, and that the difference is large enough to matter to the decision. The failure tends to concentrate further in higher-demand situations, such as grafted bone and the upper jaw, which are precisely the cases an ambitious full-arch plan piles on top of each other.

That is the number a careful consent conversation puts on the table. “About double, concentrated in the harder cases, still likely to succeed but at higher risk.” Anything that drops the “about double” has stopped being consent and started being marketing.

The mechanism: a healing site starved of oxygen

Osseointegration, the process by which living bone forms a direct structural bond with the implant surface, is a healing process, and healing is hungry for oxygen and blood flow [4]. Smoking attacks exactly those inputs, through several routes that converge on the same outcome.

Nicotine is a vasoconstrictor: it narrows blood vessels, reducing blood flow and therefore oxygen and nutrient delivery to tissue [3]. At a surgical site that needs maximal perfusion to lay down new bone and heal soft tissue, that constriction is working directly against the repair. Cigarette smoke also contains carbon monoxide, which binds hemoglobin and lowers the blood’s oxygen-carrying capacity, compounding the deficit [2]. And smoke carries a large mix of toxins that impair the bone-forming osteoblasts and the immune cells responsible for fighting infection and clearing debris from the wound [2]. There is, on top of all this, a direct local insult to the gum tissue and a heat and chemical exposure at the surgical site itself.

  Cigarette smoking
        |
   +----+--------------------+------------------+
   v                         v                  v
 Nicotine:              Carbon monoxide:     Smoke toxins:
 blood vessels          binds hemoglobin,    impair osteoblasts
 constrict              lowers oxygen-        and immune cells
   |                    carrying capacity       |
   v                         v                  v
 Less blood flow        Less oxygen           Slower bone
 to healing site        delivered             formation, worse
   |                         |                infection control
   +-----------+-------------+------------------+
               v
   Healing site starved of oxygen and blood,
   with impaired bone-building cells
               |
               v
   Impaired osseointegration:
   higher early failure, more peri-implant disease,
   poorer soft-tissue healing

Concede the limits of the mechanistic story. The exact contribution of each pathway, and the precise dose-response with how much a person smokes, are not pinned down with the confidence of the simple outcome data. The mechanism is a plausible, well-supported explanation for a robust observation, not a precise predictive model. But it explains why the effect shows up most where healing demand is highest, in grafted bone and the maxilla, and why short-term cessation around surgery is so widely recommended.

Cessation: a reasonable step, honestly bounded

It is common clinical practice to ask patients to stop smoking before and after implant surgery, on the rationale that improving the perfusion and oxygen environment around the surgical window should help healing [1]. That recommendation is sensible and low-harm, and a patient who wants to give their implant the best chance has every reason to follow it, ideally with proper cessation support rather than willpower alone.

But honesty requires bounding the claim. The evidence that smoking raises implant risk is far firmer than the evidence quantifying exactly how much a short pre- and post-operative quit recovers. Cessation around surgery should be offered as a reasonable, evidence-aligned step, not sold as a guarantee that erases the risk. A clinic that frames a few smoke-free days as fully cancelling a doubled failure rate has swung back into the rounding-down problem from the other direction. The durable benefit of quitting is to your whole body, and the CDC framing of smoking as a leading cause of preventable disease is the larger reason to stop, with the implant as a secondary motivator [2].

Why the number gets rounded down abroad

The structural argument is the heart of this piece. Why would the smoking risk be disclosed more fully at home than abroad, when the biology is identical everywhere?

Because the incentives differ. A roughly doubled failure rate is a real disincentive to a buyer, and a clinic that depends on closing a booked, fixed-itinerary trip has a commercial reason to soften it. The softening has cover: because many smokers genuinely do succeed, “we do this all the time” is literally true, and the patient cannot easily tell a fair summary from a sales one. Crucially, on the one-trip model the clinic externalises the cost of being wrong. An implant that fails to integrate often declares itself weeks to months after placement, by which time the patient is home and the failure is somebody else’s problem to diagnose and revise. The clinic captured the revenue; the patient and their home dentist inherit the failure.

That asymmetry, revenue captured up front and cost deferred and exported, is the same engine behind package-deal overtreatment and the broader dental tourism trust gap. The home dentist, embedded in a continuing relationship and likely to be the one managing any failure, has every reason to state the risk straight. The smoking conversation is where you can hear the incentive in the room: listen for whether the failure rate is named, or merely waved away. How honestly that conversation goes is one of the real inputs to the question of when to go overseas for dental treatment at all.

What a patient should verify

This is a decision framework, not treatment advice, and the cessation decisions here belong with a clinician who can support them. But three concrete items reveal whether the smoking risk was disclosed honestly or rounded away.

1. Ask for the failure rate quoted to a smoker, in numbers, not adjectives. A clinic disclosing honestly can tell you that implant failure in smokers runs roughly double that of non-smokers and that the difference is larger in grafted and upper-jaw sites. A clinic that answers only with “implants work fine in smokers” has given you the marketing summary. The presence or absence of an actual number is the tell.

2. Ask whether your smoking status changed the plan at all. Honest planning may stage the work differently, favour sites and approaches with lower healing demand, recommend cessation support, or document the raised risk in writing. A plan that is byte-for-byte identical to a non-smoker’s plan, with no acknowledgement of the difference, is a plan that did not account for the risk it told you was negligible.

3. Ask who manages a failure that appears after you fly home, and what it costs. Because the smoker’s elevated risk lands disproportionately in the months after the trip, the answer to “who fixes it and who pays” is part of the real price. A clinic confident in its disclosure will have an answer. A clinic that downplayed the risk usually has not thought past the sale.

The one number that changes the plan

Reduce it to a single figure and the smoking story is just this: about double. That is the number a smoker should carry into the decision, alongside the equally true fact that most implants in smokers still succeed. Hold both at once and you are reasoning honestly. Drop either one and you have been either frightened or sold to.

The home pathway tends to state the number plainly, not from superior virtue but because the dentist who discloses it is also the dentist likely to manage the failure, and is embedded in a relationship that does not end at the sale. The overseas one-trip pathway has a standing incentive to round it down, with the true success of many smokers as ready-made cover, while the cost of a deferred failure is exported back to the patient. The smoking case sits alongside the rest of What the Intake Form Skips, from the HbA1c that catches undiagnosed diabetes to the blood-pressure screen that gates a long sedation session and the drug-interaction void around prescribed antibiotics. In each, the protection is cheap and the incentive to skip it is structural. For how we weigh evidence and source these claims, see our methodology.

The second wave of this series extends the same argument into finer cells: how cabin altitude lowers wound oxygenation, the All-on-4 and long-haul-flight DVT pairing, and why “healed enough to crown” is a judgement a photo cannot make.